In vitro and in vivo experimental models for drug screening and development for Chagas disease
Título del documento: In vitro and in vivo experimental models for drug screening and development for Chagas disease
Revista: Memorias do Instituto Oswaldo Cruz
Base de datos: PERIÓDICA
Número de sistema: 000354839
ISSN: 0074-0276
Autores: 1
1
1
1
4
5
4
4
3
2
6
7
4
8
9
10
11
6
5
4
12
1
13
3
1
Instituciones: 1Fundacao Instituto Oswaldo Cruz, Programa Integrado de Doenca de Chagas, Rio de Janeiro. Brasil
2Fundacao Instituto Oswaldo Cruz, Instituto Rene Rachou, Belo Horizonte, Minas Gerais. Brasil
3Fundacao Instituto Oswaldo Cruz, Instituto Oswaldo Cruz, Rio de Janeiro. Brasil
4Drugs for Neglected Disease Initiative, Ginebra. Suiza
5Universidade Federal de Ouro Preto, Departamento de Ciencias Biologicas, Ouro Preto, Minas Gerais. Brasil
6Instituto de Investigaciones Científicas y Servicios de Alta Tecnologia-AIP, Clayton. Panamá
7Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais. Brasil
8Medecins sans Frontieres, Ginebra. Suiza
9Instituto Conmemorativo Gorgas de Estudios de la Salud, Ciudad de Panamá. Panamá
10University of Georgia, Center for Tropical and Emerging Global Diseases, Athens, Georgia. Estados Unidos de América
11Center for Neglected Diseases Drug Discovery, Gyeonggi-do. Corea del Sur
12Fundacao Instituto Oswaldo Cruz, Instituto Goncalo Moniz, Salvador, Bahia. Brasil
13Murdoch University, Murdoch, Western Australia. Australia
Año:
Periodo: Mar
Volumen: 105
Número: 2
Paginación: 233-238
País: Brasil
Idioma: Inglés
Tipo de documento: Artículo
Enfoque: Experimental
Resumen en inglés Chagas disease, a neglected illness, affects nearly 12-14 million people in endemic areas of Latin America. Although the occurrence of acute cases sharply has declined due to Southern Cone Initiative efforts to control vector transmission, there still remain serious challenges, including the maintenance of sustainable public policies for Chagas disease control and the urgent need for better drugs to treat chagasic patients. Since the introduction of benznidazole and nifurtimox approximately 40 years ago, many natural and synthetic compounds have been assayed against Trypanosoma cruzi, yet only a few compounds have advanced to clinical trials. This reflects, at least in part, the lack of consensus regarding appropriate in vitro and in vivo screening protocols as well as the lack of biomarkers for treating parasitaemia. The development of more effective drugs requires (i) the identification and validation of parasite targets, (ii) compounds to be screened against the targets or the whole parasite and (iii) a panel of minimum standardised procedures to advance leading compounds to clinical trials. This third aim was the topic of the workshop entitled Experimental Models in Drug Screening and Development for Chagas Disease, held in Rio de Janeiro, Brazil, on the 25th and 26th of November 2008 by the Fiocruz Program for Research and Technological Development on Chagas Disease and Drugs for Neglected Diseases Initiative. During the meeting, the minimum steps, requirements and decision gates for the determination of the efficacy of novel drugs for T. cruzi control were evaluated by interdisciplinary experts and an in vitro and in vivo flowchart was designed to serve as a general and standardised protocol for screening potential drugs for the treatment of Chagas disease
Disciplinas: Biología,
Química,
Medicina
Palabras clave: Parasitología,
Química farmacéutica,
Terapéutica y rehabilitación,
Trypanosoma cruzi,
Tratamiento,
Enfermedad de Chagas,
Monitoreo,
Fármacos,
Benznidazol
Keyword: Biology,
Chemistry,
Medicine,
Parasitology,
Medicinal chemistry,
Therapeutics and rehabilitation,
Trypanosoma cruzi,
Treatment,
Chagas disease,
Monitoring,
Drugs,
Benznidazole
Texto completo: Texto completo (Ver PDF)